|Year : 2012 | Volume
| Issue : 1 | Page : 4-6
Mitomycin C in ophthalmology
Rekha Mudhol1, ND Zingade2, RS Mudhol2
1 Department of Ophthalmology, J. N. Medical College, Belgaum, India
2 Department of ENT, J. N. Medical College, Belgaum, India
|Date of Web Publication||21-May-2012|
Department of Ophthalmology, J. N. Medical College, Belgaum - 590 010
Source of Support: None, Conflict of Interest: None
Introduction to the use of Mitomycin C in ophthalmology was a significant development in the 1960s. Its use and application in ophthalmology has been increasing in recent years, because of its modulatory effects on wound healing. Current applications of this drug in ophthalmology include pterygium surgery, glaucoma surgery, corneal refractive surgery, cicatricial eye disease, conjunctival neoplasia, dacryocystorhinostomy surgeries, squint surgeries, and allergic eye disease. Although it has been used successfully in these conditions, it has also been associated with significant complications. This article reviews the current trends and uses of mitomycin C in the eye and its reported complications.
Keywords: Mitomycin C, ophthalmology, eye disease
|How to cite this article:|
Mudhol R, Zingade N D, Mudhol R S. Mitomycin C in ophthalmology. J Sci Soc 2012;39:4-6
| Introduction|| |
Mitomycin C is an antineoplastic / antibiotic agent isolated from the soil bacterium Streptomyces caespitosus. The drug is also referred to as Mitomycin C, to differentiate it from Mitomycin A and B, which under certain conditions are also produced by Streptomyces caespitosus.
Mitomycin-C, first found its way into ophthalmic use in 1969, in Japan, where recurrent pterygia were successfully treated with the drug. 
Clinical pharmacology and mechanism of action
It is an anti-metabolite with anti-proliferative effect on cells showing the highest rate of mitosis by inhibiting DNA synthesis. The chemical formula is C 15 H 18 N 4 O 5 [Figure 1]. Reduction in quinine and loss of the methoxy group within the cell converts Mitomycin-C into a bifunctional or trifunctional alkylating agent. Deoxyribonucleic acid (DNA) is inhibited by cross-linking at the N position of Adenine and at 06 and N position of Guanine. The cell cycle is most affected during the late G-I and early S-phase. 
Pharmacokinetics, concentration, effect relationship, and metabolism
Mitomycin is delivered to the eye in a complete solubilized form, often in the presence of conjunctival and corneal epithelial defects, the drug is highly bioavailable to the target tissue. Its hydrophobic character favors its penetration into the epithelially denuded cornea and conjunctiva, while deterring its movements into or through the intact epithelium.  The use of Mitomycin eye drops, even at the highest dose used, does not result in any detectable levels of Mitomycin in the blood.
Mitomycin-C should be reconstituted in sterile water at neutral pH, the drug is inactivated in an acidic solution. The drug should be stored under refrigeration to preserve its potency under these conditions, Mitomycin-C is potent for a period of two weeks.
The following are the day-to-day uses of Mitomycin C in ophthalmological practice:
Uses of mitomycin C in ophthalmolgy
Mitomycin C in ocular surface tumours
- Ocular surface tumors
- Pterygium surgery
- Squint surgeries
- Refractive surgeries
- Allergic conjunctivitis
Ocular surface tumors include a variety of neoplasms originating from the squamous epithelium, melanocytes, and lymphocytic resident cells of the conjunctival stroma. Mitomycin-C selectively inhibits DNA synthesis and is cell cycle-nonspecific. Consequently, the rapid cycling tumor cells are treated, while the slow cycling stem cells are probably left unaffected. Second, topical mitomycin C can treat satellite and multifocal lesions and the entire ocular surface, obviating the need to establish the margins of excision. 
Topical mitomycin 0.4 mg / ml (0.04%) is administered four times a day for three weeks.  It has been used successfully as adjunctive therapy for controlling conjunctival and corneal squamous cell carcinoma (SCC) even in extensive recurrent disease. It has been used solely in a concentration of 0.04%. 
Mitomycin C in pterygium surgery
The pterygium is a horizontally oriented, triangular growth of abnormal tissue that invades the cornea from a base in the canthal region of the bulbar conjunctiva. Adjunctive use of Mitomycin C in pterygium surgery is reported to be a safe and effective procedure (0.2 - 0.4 mg / ml applied intraoperatively over bare sclera for 1 - 5 minutes)
Mitomycin C in dacryocystorhinostomy
- Among the most impressive results with pterygium were a double-masked, prospective trial  using doses of 0.4 mg / ml (0.04%) and 1 mg / ml four times daily for two weeks; they showed a recurrence rate of 2.2%, compared with the placebo rate of 88.9% after five months of follow-up. The weaker dose of mitomycin C had fewer side effects, with equal efficacy.
- Other reports also describe good results with no serious complications using 0.2 mg / ml of mitomycin C. 
- A detailed report of 10 cases with serious, vision-threatening complications associated with mitomycin C use after pterygium surgery has been published  when a concentration of 0.4 mg / ml was used postoperatively for up to three weeks. The complications included iritis (eight patients), severe secondary glaucoma (four patients), corneal edema (three patients), corectopia (two patients), sudden-onset mature cataracts (two patients), scleral calcification (one patient), and corneal perforation (one patient).
Scarring and fibrous tissue growth over the sewn flaps and osteotomy site is a major cause of DCR failure. From a past study, the most frequent cause of postoperative failure is the fibrous obstruction of common canaliculus and the osteotomy site.  In DCR surgery, Mitomycin C is used over the osteotomy site and anastomosed flaps, to suppress fibrous proliferation and scar formation. Intraoperative MMC is effective in maintaining a larger osteotomy size. This modification may possibly improve the success rates over the traditional DCR procedures.  A dose ranging from 0.02 to 0.04% applied for a duration of 5 to 30 minutes is effective.
Mitomycin C in squint surgery
Ocular motility dysfunction following ocular surgery can result from postoperative scarring and adhesions. The intraoperative application of mitomycin C is a safe and effective adjunct to surgery in the treatment of restrictive strabismus.  Mitomycin C when applied intraoperatively (0.2 mg / ml for 5 minutes) helps in reducing postoperative adhesions following strabismus surgery.
Mitomycin C in refractive surgeries
Photorefractive Keratotomy (PRK) in high myopia remains a challenge due to its complications of haze and regression reported in previous experiments, and also the success rate of laser-assisted in situ keratomileusis (LASIK) in these patients.  Using mitomycin-C in PRK for myopia greater than - 5.00 D seems safe and effective, and can reduce haze formation after surgery; therefore, it can be considered a suitable alternative for patients with myopia greater than - 5.00 D, whose corneas lack an appropriate thickness to perform LASIK, with a desirable optical zone. With this method, vision can be corrected with a better quality of vision regarding contrast sensitivity.
Mitomycin C in allergic conjunctivitis
Sodhi PK et al.  concluded in their study that topical MMC (0.2 mg / 10 ml) four times a day for three months is a safe and effective alternative to topical azelastine, in treating allergic conjunctivitis.
Complications of mitomycin C
Major complications: Rare
- Ocular pain
- Lid edema
- Foreign body sensation (secondary to superficial punctate keratitis)
Contraindications for topical use
- Scleral ulceration
- Necrotizing scleritis
- Symblepharon formation
- One-eyed patients
- Very old patients
- Pregnant women
- Those with predisposing condition to corneal ulceration or poor healing such as immunocompromised patients or patients with Sjogren's syndrome, atopic keratoconjunctivitis, acne rosacea or herpetic keratitis.
| Conclusion|| |
The dose and duration of application of Mitomycin C is still controversial. Randomized trials with longer follow-ups are needed to further establish the safety and efficacy of this drug.
| References|| |
|1.||Kunitomoro N, Mori S. Studies on pterygium: Part 4, a treatment of pterygium by Mitomycin-C installation. Acta Soc Ophthalmol Jpn 1969;67:601-7. |
|2.||Zimmerman TJ, Karanjit SK, Mordechai S. Mitomycin treatment of Corneal Disease. In: Zimmerman TJ, editor. Textbook of Ocular Pharmacology. Section IV, Vol. 56. New York: Lippincott-Raven Publishers; 1997. p. 667-9. |
|3.||Salmon SE, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, editors. Basic and clinical pharmacology. 6 th ed. Norwalk, CT: Appleton and Lange; 1995. Chap. 56. |
|4.||Hirst LW. Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: Early resolution. Ophthalmology 2007;114:976-82. |
|5.||Shields CL, Naseripour M, Shields JA. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol 2002;133:601-6. |
|6.||Singh G, Wilson MR, Foster CS. Mitomycin-C eye drops as treatment for pterygium. Ophthalmology 1998;95:813-21. |
|7.||Hayasaka S, Noda S, Yamamoto Y. Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 1988;106:715. |
|8.||Rubinfeld RS, Stein RM. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 1992;99:1647-54. |
|9.||Allen K, Berlin AJ. DCR failure: Association with nasolacrimal silicone intubation. Ophthalmic Surg 1989;20:486-9. |
|10.||Kao SC, Liao CL, Tseng JH, Chen MS, Hou PK. Dacryocystorhinostomy with intraoperative mitomycin C. Ophthalmology 1997;104:86-91. |
|11.||Chen PL, Chen WY, Lu DW. Evaluation of mitomycin C in reducing postoperative adhesions in strabismus surgery. J Ocul Pharmacol Ther 2005;21:406-10. |
|12.||Carones F, Vigo L, Scandola E, Vacchini L. Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. J Cataract Refract Surg 2002;28:2088-95. |
|13.||Sodhi PK, Pandey RM, Ratan SK. Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis. Cornea 2003;22:210-3. |
|This article has been cited by|
||History, presence, and future of mitomycin C in glaucoma filtration surgery
| ||Jarno E.J. Wolters,Ralph J.S. van Mechelen,Rana Al Majidi,Leonard Pinchuk,Carroll A.B. Webers,Henny J.M. Beckers,Theo G.M.F. Gorgels |
| ||Current Opinion in Ophthalmology. 2021; 32(2): 148 |
|[Pubmed] | [DOI]|
||Assessment of corneal endothelial cell changes caused by mitomycin-C application during pterygium surgery
| ||TarekM Radwan,AhmedA Abdelghany,AmrA.F Ali,AhmedA.B Abdel Aal |
| ||Journal of the Egyptian Ophthalmological Society. 2019; 112(3): 67 |
|[Pubmed] | [DOI]|
||Mitomycin-C Use and Complications in Ophthalmology
| ||Tongabay Cumurcu |
| ||International Journal of Clinical and Experimental Ophthalmology. 2017; 1(1): 029 |
|[Pubmed] | [DOI]|